Leaflet REMOVAB 50mcg / 0.5ml concentrate for solution for infusion
Indicated for: malignant ascites
Route of administration: infusion
Substance: catumaxomab (monoclonal antibody)
ATC: L01FX03 (Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Catumaxomab is a trifunctional monoclonal antibody used for the treatment of malignant ascites associated with epithelial cancers. It works by binding tumor cells, T cells, and accessory immune cells, thereby stimulating a strong immune response against cancer cells.
The medication is administered intraperitoneally, allowing localized action on tumor cells in the abdominal cavity. It is particularly indicated for patients who do not respond to standard therapies or are not eligible for other treatment options.
Patients should be closely monitored during treatment to detect potential adverse reactions, such as fever, abdominal pain, or hypersensitivity symptoms. It is important that the treatment is administered under strict medical supervision.
Common side effects include fever, nausea, vomiting, abdominal pain, and fatigue. In rare cases, severe allergic reactions may occur. Patients should inform their doctor of any unusual symptoms.
General data about REMOVAB 50mcg / 0.5ml
- Substance: catumaxomab
- Date of latest medicines list: 01-07-2015
- Product code: W54344001
- Concentration: 50mcg / 0.5ml
- Pharmaceutical form: concentrate for solution for infusion
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Concentrations available for catumaxomab
- 10mcg/0.1ml
- 50mcg/0.5ml